A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Turning Point Therapeutics, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: TPX-0131Experimental Treatment1 Intervention
The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Local Institution - 2108Boston, MA
Massachusetts General HospitalBoston, MA
Sarah Cannon Research Institute at Tennessee OncologyNashville, TN
Virginia Cancer SpecialistsFairfax, VA
More Trial Locations
Loading ...
Who is running the clinical trial?
Turning Point Therapeutics, Inc.Lead Sponsor